Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Race Oncology (RAC) raises $29.7 million in an oversubscribed share purchase plan
  • The company received applications totalling almost $44 million from 2340 shareholders, with the funds to be used to accelerate the company’s clinical and development plans
  • After scale-back, 9.9 million shares were issued at $3 each, representing 6.6 per cent of the company’s issued capital
  • Shares are trading 3.94 per cent higher this morning at $3.43 a share

Race Oncology (RAC) has raised $29.7 million in an oversubscribed share purchase plan (SPP).

The company received applications from 2340 shareholders, totalling $43.9 million. In line with the terms of the SPP, only $29.7 million will be accepted.

The SPP funds will be utilised to expedite the company’s clinical and development ambitions. The Phase 1b/2 FTO solid tumour clinical study will get $8 million in funding. In Europe, $9.2 million will be allocated for Phase 2 of the EMD AML/MDS clinical investigation. Zantrene formulations that have been improved will get $3.2 million. One million dollars will be spent on preclinical cardioprotection research. A total of $800,000 will be spent on the creation of novel molecules.

After scale-back, 9.9 million shares were issued at $3 each, representing 6.6 per cent of the company’s issued capital.

To determine the amount applications were scaled back, the company says it took into account the size of the applicant’s shareholding, the extent to which eligible shareholders have sold or bought additional shares after the record date, and the date an application was made.

The company will refund any money of those scaled back without interest.

Eligible directors Phil Lynch, Mary Harney, and Daniel Tillett all applied for their full entitlements.

Managing Director Phil Lynch says he is humbled by the high level of support from shareholders.

“The number of applications reflects enthusiasm for the significant potential of our lead drug Zantrene, and this enables us to implement our planned clinical and drug development plans across the three-pillar program. We move into 2022 in an exceptional position, with many critical, reportable milestones ahead of us,” he said.

Shares were trading 3.94 per cent higher this morning at $3.43 a share at 11.04 am AEDT.

RAC by the numbers
More From The Market Herald
Siren Gold (ASX:SNG) - Chairman, Brian Rodan

" Siren Gold (ASX:SNG) to begin scoping study at NZ gold projects

Siren Gold (ASX:SNG) will undertake a scoping study for underground development at its Big River and…

" Mad Paws (ASX:MPA) reports 199pc growth December-quarter revenue

Pet services marketplace Mad Paws (ASX:MPA) has reported operating revenue for the December quarter of $2…

" Vanadium Resources (ASX:VR8) increases stake in Steelpoortdrift Project

Vanadium Resources (A:VR8) increased its interest to 73.95 per cent in the Tier 1 Steelpoortdrift Vanadium…

" Stanmore (ASX:SMR) awards EPSA Pacific $564m open-cut mining contract

Stanmore Resources (ASX:SMR) has awarded EPSA Pacific a $564 million mining contract at its Isaac Downs…